A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial.
Study Goal
The researchers aimed to test whether a low-carbohydrate diet (LCD) combined with walking could mitigate metabolic disturbances caused by androgen deprivation therapy (ADT) in prostate cancer patients.
Results Summary
The LCD/walking intervention showed significant improvements in weight loss, insulin resistance, hemoglobin A1c, HDL, and triglycerides at 3 months, with some benefits (weight loss and HDL) persisting at 6 months. However, the primary outcome of insulin resistance reduction at 6 months was not statistically significant, likely due to the small sample size and early study termination.
Population
Prostate cancer patients initiating androgen deprivation therapy (ADT).
Effective Dosage
≤20g carbohydrate/day plus walking (≥30 min for ≥5 days/week).
Duration
6 months.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
low-carbohydrate diet (LCD) plus walking | decrease | insulin resistance | prostate cancer (PCa) patients initiating ADT | 4% | reduced | #1 |
control | increase | insulin resistance | prostate cancer (PCa) patients initiating ADT | 36% | increased | #2 |
LCD/walking | decrease | weight | prostate cancer (PCa) patients initiating ADT | 7.8kg | significantly lost | #3 |
LCD/walking | decrease | insulin resistance | prostate cancer (PCa) patients initiating ADT | ↑36% | improved | #4 |
LCD/walking | decrease | hemoglobin A1c | prostate cancer (PCa) patients initiating ADT | ↓3.3% | improved | #5 |
LCD/walking | increase | high-density lipoprotein (HDL) | prostate cancer (PCa) patients initiating ADT | ↑13% | improved | #6 |
LCD/walking | decrease | triglyceride | prostate cancer (PCa) patients initiating ADT | ↓37% | improved | #7 |
LCD/walking | decrease | weight loss | prostate cancer (PCa) patients initiating ADT | 10.6kg | remained significant | #8 |
LCD/walking | increase | HDL | prostate cancer (PCa) patients initiating ADT | ↑27% | remained significant | #9 |
LCD/walking | no change | total body bone mineral count | prostate cancer (PCa) patients initiating ADT | - | preserved | #10 |
LCD/walking | decrease | fat mass | prostate cancer (PCa) patients initiating ADT | - | reduced | #11 |
LCD/walking | decrease | lean mass | prostate cancer (PCa) patients initiating ADT | - | reduced | #12 |
LCD/walking | decrease | percent body fat | prostate cancer (PCa) patients initiating ADT | - | reduced | #13 |
LCD/walking | no change | PSA | prostate cancer (PCa) patients initiating ADT | - | no differences | #14 |
LCD/walking | no change | insulin sensitivity | prostate cancer (PCa) patients initiating ADT | - | did not improve | #15 |
LCD/walking | decrease | insulin resistance | prostate cancer (PCa) patients initiating ADT | - | reduced | #16 |
PURPOSE: The objective of this study was to test a low-carbohydrate diet (LCD) plus walking to reduce androgen deprivation therapy (ADT)-induced metabolic disturbances. MATERIALS AND METHODS: This randomized multi-center trial of prostate cancer (PCa) patients initiating ADT was designed to compare an LCD (≤20g carbohydrate/day) plus walking (≥30 min for ≥5 days/week) intervention vs. control advised to maintain usual diet and exercise patterns. Primary outcome was change in insulin resistance by homeostatic model assessment at 6 months. To detect 20% reduction in insulin resistance, 100 men were required. The study was stopped early after randomizing 42 men due to slow accrual. Secondary outcomes included weight, body composition, lipids, and prostate-specific antigen (PSA). Changes from baseline were compared between arms using rank-sum tests. RESULTS: At 6 months, LCD/walking reduced insulin resistance by 4% vs. 36% increase in control (p = 0.13). At 3 months, vs. control, LCD/walking arm significantly lost weight (7.8kg; p<0.001), improved insulin resistance (↑36%; p = 0.015), hemoglobin A1c (↓3.3%; p = 0.01), high-density lipoprotein (HDL) (↑13%; p = 0.004), and triglyceride (↓37%; p = 0.036). At 6 months, weight loss (10.6kg; p<0.001) and HDL (↑27%; p = 0.003) remained significant. LCD/walking preserved total body bone mineral count (p = 0.025), reduced fat mass (p = 0.002), lean mass (p = 0.036), and percent body fat (p = 0.004). There were no differences in PSA. Limitations include the effect of LCD, weight loss vs. walking instruction are indistinguishable, and small sample size. CONCLUSIONS: In an underpowered study, LCD/walking did not improve insulin sensitivity at 6 months. Given most secondary outcomes were improved at 3 months with some remaining improved at 6 months and a secondary analysis showed that LCD/walking reduced insulin resistance over the study, supporting future larger studies of LCD/walking intervention to reduce ADT-induced disturbances.